Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Breast Radiology · Breast Stromal Fibrosis

Benign Breast Fibrosis Biopsy: What Follow-Up Is Needed?

At a Glance

After an adequately sampled biopsy shows pure benign breast fibrosis that matches the imaging, most people return to routine age- and risk-based screening. Six-month imaging, repeat biopsy, or MRI may be needed for a mismatch, a separate probably benign finding, or elevated breast cancer risk.

In this answer

6 sections

01

What is Pure Stromal Fibrosis?

02

The Importance of Radiologic-Pathologic Concordance

03

Do I Need Short-Interval Imaging?

04

Pathology Details: Pure Fibrosis vs. Mixed Results

05

Who Needs a Supplemental Breast MRI?

06

When to Contact Your Doctor Sooner

If your biopsy shows pure benign breast fibrosis and the result is “concordant” with your imaging, you will typically be cleared to return to your routine, age- and risk-appropriate screening schedule. Having a biopsy does not automatically mean you need a short-interval follow-up scan or an MRI. Your personalized imaging plan will depend on whether the biopsy fully explained the imaging abnormality, your overall breast cancer risk, and the exact details of your pathology report. If your radiologist has specifically recommended a 6-month follow-up, do not cancel it based on this general information—ask your care team why it was recommended.

What is Pure Stromal Fibrosis?

“Breast fibrosis” (or stromal fibrosis) simply means an area of thickened, non-cancerous connective tissue. Isolated, pure stromal fibrosis is a benign finding, usually requires no specific treatment on its own, and does not mean you have cancer or an increased risk of breast cancer [1][2].

The Importance of Radiologic-Pathologic Concordance

The most crucial factor in your follow-up plan is whether your biopsy result is radiologic-pathologic concordant. This determination is made jointly by your radiologist and pathologist and should be documented in your final report.

  • Concordant: This means that finding benign breast fibrosis makes sense based on the size, shape, and appearance of the abnormality seen on your mammogram, ultrasound, or MRI. When a benign biopsy is adequately sampled and concordant, the chance of a missed cancer is extremely low (often less than 1%), and studies show that returning to your routine screening schedule is safe [3][4][5].
  • Discordant: If the benign fibrosis does not explain the suspicious area on your imaging, the result is discordant. In these cases, there is a meaningful risk (around 20% to 40% in some studies) that a cancer could be hiding nearby that the needle missed [6]. Your care team will not send you back to routine screening. Instead, they will recommend prompt diagnostic resolution, such as a repeat biopsy or surgical excision (surgery to remove the area) [6][7].

Do I Need Short-Interval Imaging?

Many patients assume they need a 6-month follow-up scan to make sure nothing was missed. Research shows that for definitively benign, concordant biopsies, a 6-month checkup rarely finds cancer and benefits very few patients [3][5].

However, short-interval surveillance (usually at 6 months) is used for other reasons:

  • You have a separate, un-biopsied finding graded as BI-RADS 3. BI-RADS is a standard system radiologists use to categorize breast imaging findings. A BI-RADS 3 score means a finding is “probably benign” but requires short-interval tracking to prove it is stable [8].
  • Your care team prefers to re-evaluate the biopsy site based on their specific local protocols or the method used for the biopsy.

Pathology Details: Pure Fibrosis vs. Mixed Results

If your pathology report shows isolated, pure fibrosis, it is treated as a straightforward benign finding. But sometimes, fibrosis is found mixed with other features.

If your biopsy shows atypia (abnormal cells) or complex structures like a radial scar, your management will be individualized [9][10]. Depending on the exact lesion, its size, and how completely it was sampled, recommendations can range from active surveillance to vacuum-assisted removal or surgical excision [11][12]. You should discuss the exact wording of your pathology report with a breast specialist to understand your options.

Who Needs a Supplemental Breast MRI?

A benign fibrosis biopsy on its own does not qualify you for a breast MRI [13]. MRIs are supplemental, risk-based screening tools, not automatic follow-ups for benign biopsies. Your doctor may recommend adding an MRI to your routine mammograms if:

  • You have a high lifetime risk: Guidelines generally recommend annual MRI screening for women with a calculated lifetime risk of breast cancer of 20% or greater [14]. Your doctor will use validated risk models that factor in your family history (especially breast, ovarian, and prostate cancers) and prior biopsies [15][16].
  • You have a genetic mutation: Women with strong family histories, genetic mutations (like BRCA1/2), or chest radiation at a young age are candidates for MRI screening [14][17].
  • You have extremely dense breasts: Dense breast tissue can mask tumors on a mammogram and slightly increases cancer risk [18][19]. Guidelines vary by country; for example, European guidelines (EUSOBI) suggest offering an MRI every 2 to 4 years for women aged 50–70 with extremely dense breasts, but this is an individualized decision [20].

Note: MRI has limitations, including higher costs, the need for intravenous contrast, and a higher rate of “false positives” that can lead to unnecessary extra biopsies [20]. It is a supplement to, not a replacement for, mammography.

Summary Follow-Up Pathways

Finding Type Description Usual Next Step
Concordant Pure Fibrosis Fibrosis fully explains the imaging finding. Return to routine, age- and risk-appropriate screening schedule.
Discordant Benign Result Benign tissue does not match or explain the imaging finding. Repeat biopsy or surgical excision for accurate diagnosis.
BI-RADS 3 Finding A separate, un-biopsied area graded as “probably benign.” Short-interval surveillance imaging (typically at 6 months).
Atypia or High-Risk Lesion Fibrosis mixed with abnormal cells or complex lesions. Individualized care plan (surveillance, additional sampling, or excision).

When to Contact Your Doctor Sooner

Even if you are cleared for routine screening, you should never wait for your next scheduled scan if you notice new breast changes. Contact your clinician promptly for an assessment if you develop a new or changing lump, skin dimpling, persistent focal pain, or spontaneous bloody nipple discharge [21][22][23]. Your care team will determine whether diagnostic imaging is needed.

Common questions in this guide

Do I need a six-month scan after a benign breast fibrosis biopsy?
Not usually if the biopsy shows pure fibrosis, adequately sampled the area, and is radiologic-pathologic concordant. Most people can return to routine screening based on age and personal risk. Follow a specific six-month recommendation until your radiologist explains what finding it is monitoring.
What does a concordant breast biopsy result mean?
It means the benign tissue found on biopsy adequately explains the abnormality seen on the mammogram, ultrasound, or MRI. The radiologist and pathologist make this assessment together. A concordant result is different from a benign result that does not explain a suspicious image.
When would I need another biopsy after benign fibrosis?
Another biopsy or surgical excision may be recommended when the benign fibrosis does not match or explain the suspicious imaging finding. This is called radiologic-pathologic discordance and can mean the needle sampled the wrong area or missed an important lesion. Prompt follow-up is important rather than waiting for routine screening.
Does benign breast fibrosis mean I need a breast MRI?
No. Pure benign fibrosis alone usually does not qualify someone for supplemental MRI. MRI may be considered when breast cancer risk is high, such as a lifetime risk of 20% or more, a relevant genetic mutation, chest radiation at a young age, or sometimes extremely dense breasts; recommendations vary.
Why might my doctor schedule six-month imaging if the biopsy was benign?
A six-month scan may be monitoring a separate unbiopsied BI-RADS 3 finding, which is probably benign but needs imaging to show stability. It may also reflect local practice or the biopsy method. Ask what exact finding is being monitored and do not cancel a recommended appointment without discussing it.
What if my biopsy also shows atypia or a radial scar?
Atypia or a radial scar can change the follow-up plan because these findings are not managed the same way as isolated pure fibrosis. Depending on the lesion and how completely it was sampled, options may include surveillance, vacuum-assisted removal, or surgical excision. A breast specialist should review the exact pathology wording with you.
Which breast changes should I report before my next screening test?
Contact your clinician promptly for a new or changing lump, skin dimpling, persistent focal pain, or spontaneous bloody nipple discharge. These symptoms do not automatically mean cancer, but they may require diagnostic assessment rather than waiting for routine screening.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my biopsy result officially documented as 'radiologic-pathologic concordant,' and did the sampled tissue fully explain the imaging finding?
  2. 2.Does my pathology report show pure stromal fibrosis, or were there additional features like atypia or a radial scar?
  3. 3.What was the final BI-RADS assessment category for this finding, and does it require short-interval surveillance?
  4. 4.Based on my breast density and family history, what is my estimated lifetime risk of breast cancer, and do I meet the 20% threshold for supplemental MRI?
  5. 5.If I was given a 6-month follow-up appointment, what specific finding is being monitored, and can you walk me through why it is necessary?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can a Needle Biopsy Worsen Breast Fibrosis or Spread a Lump?Can Benign Breast Fibrosis Cause Lumps in Both Breasts?Does Breast Fibrosis Affect Pregnancy or Breastfeeding?Can Breast Fibrosis Cause Breast Pain Like Breast Cancer?Can Dense Breasts Make Breast Fibrosis Harder to See?Does a Breast Biopsy Marker Clip Stay in Permanently?Does Benign Breast Fibrosis Increase Breast Cancer Risk?Does Breast Fibrosis Go Away? What to Expect Over TimeHow Accurate Is a Benign Breast Biopsy Showing Fibrosis?What Causes Breast Fibrosis Without Radiation Treatment?What Does Idiopathic Stromal Fibrosis Mean on Breast Biopsy?Why Is Breast Imaging Suspicious After a Benign Biopsy?Core or Vacuum-Assisted Biopsy for Breast Fibrosis?How Does Breast Scar Tissue Differ From Radiation Fibrosis?What Should a Breast Fibrosis Biopsy Report Include?Breast Fibrosis Lump After Biopsy: What Should I Do?When Is Breast MRI Recommended for Breast Fibrosis?When Does Breast Fibrosis Need Repeat Biopsy or Surgery?When Should I Get a Second Opinion for Breast Fibrosis?

References

References (23)
  1. 1

    Risk-Associated Lesions of the Breast in Core Needle Biopsies: Current Approaches to Radiological-Pathological Correlation.

    Ambinder EB, Calhoun BC

    Surgical pathology clinics 2022; (15(1)):147-157 doi:10.1016/j.path.2021.11.010.

    PMID: 35236630
  2. 2

    Demystifying Breast Disease Markers.

    Wells VA, Medeiros I, Shevtsov A, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2023; (43(10)):e220151 doi:10.1148/rg.220151.

    PMID: 37676826
  3. 3

    Six-Month Short-Interval Imaging Follow-Up for Benign Concordant Core Needle Biopsy of the Breast: Outcomes in 1444 Cases With Long-Term Follow-Up.

    Monticciolo DL, Hajdik RL, Hicks MG, et al.

    AJR. American journal of roentgenology 2016; (207(4)):912-917 doi:10.2214/AJR.15.15853.

    PMID: 27340732
  4. 4

    Utility of short-interval follow-up mammography after a benign-concordant stereotactic breast biopsy result.

    Maldonado S, Gandhi N, Ha T, et al.

    Breast (Edinburgh, Scotland) 2018; (42()):50-53 doi:10.1016/j.breast.2018.08.101.

    PMID: 30172804
  5. 5

    Short-term follow-up in 6 months is unnecessary for asymptomatic breast lesions with benign concordant results obtained at ultrasonography-guided 14-gauge core needle biopsy.

    Moon HJ, Jung I, Youk JH, et al.

    American journal of surgery 2016; (211(1)):152-8.

    PMID: 26381659
  6. 6

    Radiologic-Pathologic Discordance After Image-Guided Breast Biopsy: A Systematic Review of Prevalence and Outcomes.

    Yincharoen P, Sharma CP, Tawanwongsri W

    Medical sciences (Basel, Switzerland) 2026; (14(2)) doi:10.3390/medsci14020229.

    PMID: 42201021
  7. 7

    [Interpretation of Image-Guided Biopsy Results and Assessment].

    Ha SM, Chang JM

    Journal of the Korean Society of Radiology 2023; (84(2)):361-371 doi:10.3348/jksr.2022.0164.

    PMID: 37051381
  8. 8

    Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database.

    Berg WA, Berg JM, Sickles EA, et al.

    Radiology 2020; (296(1)):32-41 doi:10.1148/radiol.2020192641.

    PMID: 32427557
  9. 9

    High-Risk Breast Lesions on Core Biopsy: Rates of Upgrade and Management Recommendations.

    Grabenstetter A

    Surgical pathology clinics 2025; (18(4)):707-723 doi:10.1016/j.path.2025.05.001.

    PMID: 41224414
  10. 10

    Rethinking Routine Surgical Excision for all Radial Sclerosing Lesions of the Breast.

    Patel M, Aripoli A, Chollet-Hinton L, et al.

    The Journal of surgical research 2022; (279()):611-618 doi:10.1016/j.jss.2022.06.048.

    PMID: 35926311
  11. 11

    Architectural Distortions Detected by DBT Alone With No Ultrasound Correlate and Nonmalignant Results on Core Needle Biopsy: Outcomes From an Imaging-Focused Management Strategy.

    Nguyen DL, Langman EL, Johnson KS, Grimm LJ

    AJR. American journal of roentgenology 2025; (224(5)):e2532737 doi:10.2214/AJR.25.32737.

    PMID: 40071902
  12. 12

    Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

    Elfgen C, Leo C, Kubik-Huch RA, et al.

    Virchows Archiv : an international journal of pathology 2023; (483(1)):5-20 doi:10.1007/s00428-023-03566-x.

    PMID: 37330436
  13. 13

    Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR.

    Monticciolo DL, Newell MS, Moy L, et al.

    Journal of the American College of Radiology : JACR 2018; (15(3 Pt A)):408-414 doi:10.1016/j.jacr.2017.11.034.

    PMID: 29371086
  14. 14

    Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR.

    Monticciolo DL, Newell MS, Moy L, et al.

    Journal of the American College of Radiology : JACR 2023; (20(9)):902-914 doi:10.1016/j.jacr.2023.04.002.

    PMID: 37150275
  15. 15

    Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer.

    Tice JA, Miglioretti DL, Li CS, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(28)):3137-43 doi:10.1200/JCO.2015.60.8869.

    PMID: 26282663
  16. 16

    Family history of breast cancer, mammographic breast density and breast cancer risk: Findings from a cohort study of Korean women.

    Mai Tran TX, Kim S, Song H, Park B

    Breast (Edinburgh, Scotland) 2022; (65()):180-186 doi:10.1016/j.breast.2022.08.008.

    PMID: 36049384
  17. 17

    Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.

    Wood ME, McKinnon W, Garber J

    The breast journal 2020; (26(8)):1528-1534 doi:10.1111/tbj.13969.

    PMID: 32741080
  18. 18

    Association between mammographic breast density and histologic features of benign breast disease.

    Ghosh K, Vierkant RA, Frank RD, et al.

    Breast cancer research : BCR 2017; (19(1)):134 doi:10.1186/s13058-017-0922-6.

    PMID: 29258587
  19. 19

    Clinical guidelines for the management of mammographic density: a systematic review of breast screening guidelines worldwide.

    Isautier JMJ, Houssami N, Hadlow C, et al.

    JNCI cancer spectrum 2024; (8(6)) doi:10.1093/jncics/pkae103.

    PMID: 39392432
  20. 20

    Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI).

    Mann RM, Athanasiou A, Baltzer PAT, et al.

    European radiology 2022; (32(6)):4036-4045 doi:10.1007/s00330-022-08617-6.

    PMID: 35258677
  21. 21

    Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text.

    Lavoué V, Fritel X, Antoine M, et al.

    European journal of obstetrics, gynecology, and reproductive biology 2016; (200()):16-23.

    PMID: 26967341
  22. 22

    Clinically guided core biopsy and cutaneous punch biopsy in the evaluation of breast lesions: a necessary test or an obsolete skill?

    Alameer A, Common M, Elwahab SA, et al.

    Irish journal of medical science 2023; (192(1)):317-319 doi:10.1007/s11845-022-02937-8.

    PMID: 35132568
  23. 23

    Clinical abnormalities of the nipple-areola complex: The role of imaging.

    Geffroy D, Doutriaux-Dumoulins I

    Diagnostic and interventional imaging 2015; (96(10)):1033-44.

    PMID: 26385836

This page explains follow-up after a benign breast fibrosis biopsy for educational purposes and is not medical advice. Your radiologist and breast specialist should interpret your reports and decide whether routine screening, short-interval imaging, or MRI is appropriate.

Get notified when new evidence is published on breast fibrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.